This is very important and removes much doubt I had previously. Emory is conduction a trial like the NeuralStem trial minus the stem cells to see if it was the immune drugs that were causing the improvement. In the this presentation she said the trial is now closed to enrollment and she said they wanted to determine if it was the immune meds that was causing an improvement in the patients. She said so far the answer to this appears to be NO, its not the immune meds.
Google: youtube eva feldman michigan. It's dated Aug 12th.
I bought more shares today because of this.
We need a day of rage for this. Or a week of rage
I would agree. But where is the outrage for all of the children being shot in Chicago by black men? It happens almost every week. Let's have a day of rage for this. I will attend.
The court ruled in favor of not dismissing the case. Even if STEM prevailed they don't own the data CUR has collected. They would need to start from ground zero with animal studies.
They also would not be able to conduct the same trial because CUR has patented the device used to administer cells. This device might be why CUR is showing strong efficacy and STEM is not.
American Mold Guard, Inc. (AMGI)
For the sake of the patients I hope it works but I think you are correct. The efficacy data was marginal but if they can add a few months of life to a subgroup that would be great. Unless they have extremely positive data the FDA process is going to be slow.
Anyone referencing the "basher handbook" is a complete nut job. "Those who manage the Basher" ... LOL
Go put your money in a CD or you will be another message board idiot who lost their savings and blames it on paid BASHERS. The yahoo message boards are filled with people like you.
All the the legal issues come from STEM which is desperate as a result of weak efficacy signals in its trials and the threat of a reverse split to stay listed.
What's wrong with selling he company? I will make lots of money and Imetelstat will be in the hands of a company with organizational strength to bring it to market and help patients.
You know you are going to have a melt down when the CC just ends up being a high level overview and PW introducing himself. In 3 weeks on the job he's not going to have some great revelation. The only thing useful I have gotten out of CC's is earning guidance and ACTC doesn't have earnings.
"Other opportunities" is code word for being asked to leave.... fired.
If it was his choice to leave he would be leaving for another "opportunity"
Yes. Who ever owned the stock on the ex-dividend date will eventually end up with the shares. Don't listen to the message board non-sense about the record date.